Sinopharm Group Balance Sheet Health
Financial Health criteria checks 6/6
Sinopharm Group has a total shareholder equity of CN¥120.3B and total debt of CN¥68.6B, which brings its debt-to-equity ratio to 57%. Its total assets and total liabilities are CN¥383.4B and CN¥263.1B respectively. Sinopharm Group's EBIT is CN¥22.3B making its interest coverage ratio 10.3. It has cash and short-term investments of CN¥67.1B.
Key information
57.0%
Debt to equity ratio
CN¥68.56b
Debt
Interest coverage ratio | 10.3x |
Cash | CN¥67.14b |
Equity | CN¥120.32b |
Total liabilities | CN¥263.08b |
Total assets | CN¥383.39b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 1099's short term assets (CN¥336.8B) exceed its short term liabilities (CN¥241.5B).
Long Term Liabilities: 1099's short term assets (CN¥336.8B) exceed its long term liabilities (CN¥21.6B).
Debt to Equity History and Analysis
Debt Level: 1099's net debt to equity ratio (1.2%) is considered satisfactory.
Reducing Debt: 1099's debt to equity ratio has reduced from 80.6% to 57% over the past 5 years.
Debt Coverage: 1099's debt is well covered by operating cash flow (25%).
Interest Coverage: 1099's interest payments on its debt are well covered by EBIT (10.3x coverage).